In one instance, North Korean hackers targeted at least six pharmaceutical companies in the U.S., the UK and South Korea working on COVID-19 treatments, according to sources familiar with the matter.
The firms include in the U.S.: Johnson & Johnson and Maryland-based Novavax Inc., which are both working on experimental vaccines, the sources said. The list also includes three South Korean companies with Covid-19 drugs in earlier clinical trials, Genexine Inc., Shin Poong Pharmaceutical Co. and Celltrion Inc., they added in a published report.
North Korea had also tried infiltrating U.K.-based AstraZeneca PLC, whose vaccine co-developed with the University of Oxford, has been shown to be as much as 90% effective and is seeking emergency approval, the sources said. On Friday, Reuters reported that suspected North Korean hackers had tried to break into the systems of AstraZeneca, citing unnamed sources.
It wasn’t known whether the hackers succeeded in swiping useful information. But North Korea has coordinated attacks on the six companies since August, the sources said.
Digital Fingerprints
The attacks contained digital fingerprints used in other North Korean campaigns against the State Department and South Korea’s unification ministry, such as the use of the same IP addresses, the people said.
“The problem is that we ‘see’ cyberattacks and do not prevent them upfront,” said Eddy Bobritsky, chief executive at cybersecurity provider, Minvera Labs. “We need to evolve our defense strategy to be resilient for cyberattacks and prevent attacks at the beachhead stage. Critical assets need to be hidden so they will be invisible and unreachable for malware-based cyberattacks.”
Healthcare organizations like Johnson & Johnson are seeing cyber-attacks from nation-state threat actors “every single minute of every single day,” said Marene Allison, chief information security officer at Johnson & Johnson last week. “Healthcare companies literally have seen an onslaught [of cyberattacks] since March 2010,” Allison said on Thursday in an online panel at the Aspen Cyber Summit, published on ZDNet.
This latest information comes on the heels of an IBM Security X-Force report on COVID-19 cyber threats against organizations keeping the vaccine supply chain moving. As part of these efforts, the X-Force team uncovered a global phishing campaign targeting organizations associated with a COVID-19 cold chain. The cold chain is a component of the vaccine supply chain that ensures the safe preservation of vaccines in temperature-controlled environments during their storage and transportation.
September Startup
The X-Force report found this operation started in September 2020. The COVID-19 phishing campaign spanned across six countries and targeted organizations likely associated with Gavi, The Vaccine Alliance’s Cold Chain Equipment Optimization Platform (CCEOP) program. While X-Force could not establish firm attribution for this campaign, the precision targeting of executives and key global organizations hold the potential hallmarks of nation-state tradecraft.
Some details from IBM Security X-Force’s analysis of this activity include:
- The adversary impersonated a business executive from Haier Biomedical, a credible and legitimate member company of the COVID-19 vaccine supply chain and qualified supplier for the CCEOP program. The company is purportedly the world’s only complete cold chain provider. Disguised as this employee, the adversary sent phishing emails to organizations believed to be providers of material support to meet transportation needs within the COVID-19 cold chain. The purpose of this COVID-19 phishing campaign may have been to harvest credentials, possibly to gain future unauthorized access to corporate networks and sensitive information relating to the COVID-19 vaccine distribution.
- The targets included the European Commission’s Directorate-General for Taxation and Customs Union, as well as organizations within the energy, manufacturing, website creation and software and Internet security solutions sectors. These are global organizations headquartered in Germany, Italy, South Korea, Czech Republic, greater Europe and Taiwan.
- Spear-phishing emails ended up sent out to select executives in sales, procurement, information technology and finance positions, likely involved in company efforts to support a vaccine cold chain. We also identified instances where this activity extended organization-wide to include help and support pages of targeted organizations.
Recommendations
IBM Security X-Force urged companies in the COVID-19 supply chain — from research of therapies, healthcare delivery to distribution of a vaccine — to be vigilant and remain on high alert during this time. Governments have already warned foreign entities are likely to attempt to conduct cyber espionage to steal information about vaccines.
X-Force uncovered targets across multiple industries, governments and global partners that support the CCEOP program. The CCEOP ended up launched by Gavi, The Vaccine Alliance along with the United Nations Children Fund (UNICEF) and other partners in 2015. Its objective is to ultimately strengthen vaccine supply chains, optimize immunization equity and ensure an agile medical response to outbreaks of infectious diseases. Various classes of medication, and especially vaccines, require storage and transport in temperature-controlled environments to ensure their safe preservation.
The CCEOP initiative is naturally accelerating efforts to facilitate the distribution of a COVID-19 vaccine. A breach within any part of this global alliance could result in the exposure of numerous partner computing environments worldwide, according to the X-Force report.
The spoofed phishing emails appear to originate from a business executive from Haier Biomedical, a Chinese company currently acting as a qualified supplier for the CCEOP program, in coordination with the World Health Organization (WHO), UNICEF and other U.N. agencies. It is highly likely the adversary strategically chose to impersonate Haier Biomedical because it is purported to be the world’s only complete cold chain provider, according to the X-Force report. Likewise, the Haier Biomedical employee sending these emails would likely be associated with Haier Biomedical’s cold chain distribution operations based on his role, listed in the email signature block.
Probability of Success
It’s unclear from our analysis if the COVID-19 phishing campaign was successful, X-Force researchers said. However, the established role Haier Biomedical plays in vaccine transport, and their likely role in COVID-19 vaccine distribution, increases the probability the intended targets may engage with the inbound emails without questioning the sender’s authenticity.
Given the specialization and global distribution of organizations targeted in this campaign, it’s highly likely the adversary is intimately aware of critical components and participants of the cold chain.
Attackers, according to the X-Force report, appear to target:
- European Commission’s directorate-general for taxation and customs union — The Directorate-General is responsible for promoting cooperation on customs and tax matters across the EU. It maintains direct ties to multiple national government networks and is associated with trade and regulation. Targeting this entity could serve as a single point of compromise impacting multiple high-value targets across the 27 member states of the European Union and beyond.
- Energy sector — Spear phishing targets included companies involved in manufacturing solar panels. One of the ways that vaccines are kept cold in countries where reliable power is not possible is by using vaccine refrigerators powered by solar panels. A compromise of such technologies could result in intellectual property theft or stealing and selling vaccine shipping containers in black markets across the globe. Targeting also included companies associated with petrochemicals. Among the key components of cold chain is the use of dry ice, which is a byproduct of petroleum production.
- IT sector — Amongst the targets were a South Korean software development firm and a German website development company. The latter supports multiple clients associated with pharmaceutical manufacturers, container transport, biotechnology and manufacturers of electrical components enabling sea, land and air navigation and communications.

